Crism losses widen as it spends on clinical development

(Sharecast News) - Crism Therapeutics reported a wider full-year loss on Friday, reflecting increased investment in clinical and pre-clinical development as it prepared to start a Phase 2 trial of irinotecan-ChemoSeed in glioblastoma.

The AIM-traded company said its loss for 2025 widened to £1.90m from £0.61m, with R&D expenditure rising to £908,000.

Total assets were broadly stable at £1.79m, while cash stood at £1.13m at year-end.

During the year, Crism received MHRA clinical trial authorisation for an open-label, registration-grade Phase 2 trial in surgically resectable glioblastoma, and raised £1.93m before expenses through two equity fundraises.

Post year-end, the company secured FDA orphan drug designation for irinotecan-ChemoSeed, a Japanese patent, positive preclinical data for docetaxel-ChemoSeed in prostate cancer, and a further £2.75m before expenses from an oversubscribed fundraise.

It also received Innovate UK and Invest Northern Ireland grants totalling about £1.0m.

Executive chairman Andrew Webb said 2025 was "a year of significant progress", adding that Crism was "well funded" with a site initiation visit planned for late July, "the final step before patient recruitment begins".

At 1202 BST, shares in Crism Therapeutics Corporation were flat at 10p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate